Letter comments on: "Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'"

ESMO Open. 2022 Jun;7(3):100487. doi: 10.1016/j.esmoop.2022.100487. Epub 2022 May 4.

Authors

B Müller¹, R Estay²

Affiliations

¹ Instituto Nacional del Cáncer, Department for Medical Oncology, Santiago, Chile; Grupo Oncológico Cooperativo Chileno de Investigación, Santiago, Chile. Electronic address: bettina.muller@incancer.cl.
² Hospital del Salvador, Department for Medical Oncology, Santiago, Chile; School of Medicine, Eastern Campus, Universidad de Chile, Santiago, Chile.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Drug Approval
Humans
Neoplasms* / drug therapy

Substances

Antineoplastic Agents